Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 2Phase 1 2Phase EARLY_PHASE1 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Non-Small-Cell Lung 10Breast Neoplasms 8Sarcoma 5Lung Neoplasms 5Urinary Bladder Neoplasms 4Neoplasms 4Lymphoma 4Hodgkin Disease 4Uterine Cervical Neoplasms 3Thyroid Neoplasms 3Thyroid Cancer, Papillary 3Rectal Neoplasms 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Lymphoma, Large B-Cell, Diffuse 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Hepatocellular 3Adenocarcinoma, Follicular 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Pleural Effusion, Malignant 2Neuroendocrine Tumors 2Mesothelioma 2Melanoma 2Lymphoma, B-Cell 2Liver Neoplasms 2Kidney Neoplasms 2Colonic Neoplasms 2

Interventions

Docetaxel 137Prednisone 120Abiraterone Acetate 91Leuprolide 86enzalutamide 84Radiotherapy 59bicalutamide 56Magnetic Resonance Spectroscopy 54Goserelin 54Androgen Antagonists 51acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 47apalutamide 44abiraterone 34Radiosurgery 31Specimen Handling 30gallium 68 PSMA-11 29Gonadotropin-Releasing Hormone 29cabazitaxel 28Carboplatin 27darolutamide 25Estramustine 24luprolide acetate gel depot 23relugolix 22Metformin 22Triptorelin Pamoate 20sipuleucel-T 19radium Ra 223 dichloride 19Radiation 19pembrolizumab 18deltacortene 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Prostatic Neoplasms × Fluorodeoxyglucose F18 × Clear all
NCT03173924 2026-05-22

18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
96 enrolled
Genitourinary

Disease, Prostatic Neoplasms

NCT03181867 2026-04-22

18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
360 enrolled
Genitourinary

Prostatic Neoplasms

NCT06145633 2026-01-28

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

Fred Hutchinson Cancer Center

Phase 2 Recruiting
15 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡